About

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on research, development, and commercialization of these products, ensuring they meet strict regulatory standards for quality and efficacy. Coherus aims to improve patient lives by expanding access to essential biologic treatments, helping to reduce healthcare costs. Their business model allows them to generate revenue through the sale of these cost-effective alternatives, giving them a competitive advantage in the biopharmaceutical market.

Simplify's Take

What believers are saying

• Global biosimilars market projected to grow at 24.7% CAGR from 2023 to 2030.
• FDA guidance on biosimilar interchangeability could boost market acceptance for Coherus.
• Collaborations with research institutes enhance development of novel therapies.

What critics are saying

• Sandoz acquisition of Coherus' assets may lead to market share erosion.
• 30% staff reduction could impact operational efficiency and product development.
• Divestment of Canadian rights to Toripalimab limits revenue potential in Canada.

What makes Coherus BioSciences unique

• Coherus focuses on cost-effective biosimilars for oncology and inflammatory diseases.
• The company leverages advanced process science and analytical characterization in development.
• Coherus' Udenyca wearable injector offers innovative drug delivery for pegfilgrastim.

Help us improve and share your feedback! Did you find this helpful?

YesNo